Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02825901
Other study ID # N201604003
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date March 2019
Est. completion date December 2020

Study information

Verified date March 2018
Source Taipei Medical University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the trial is to evaluate the effect of Djulis-Buckwheat drink on cardiovascular protection after ingesting for 8 weeks. In addition, the correlation between the supplement and the cardiovascular disease-related gene expression is evaluated. The results will be used for the application of functional products for cardiovascular protection. Ninety subjects (age 30~65) with Prehypertension or Hypertension stage 1 will be included and randomly allocated into 3 groups: Placebo, Djulis-Buckwheat and Buckwheat. The subjects will take sample (100 ml/day) for 8 weeks. Blood pressure will be measured on week 0, 1, 2, 4, 6 and 8. The blood biochemical parameters and gene expression analysis will be examined on week 2, 4, 6, 8 and 10 (the follow up).


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2020
Est. primary completion date January 2020
Accepts healthy volunteers No
Gender All
Age group 30 Years to 65 Years
Eligibility Inclusion Criteria: - Systolic blood pressure 121-159 mmHg or Diastolic blood pressure 81-99 mmHg - Age: 30-65 Exclusion Criteria: - Have diagnosed and documented critical illness(NHI specification) - Had emergency record or admission note in the past three months - Not be pregnant or breast-feeding a child

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Placebo
Ingest placebo drink 100ml/day for 8 weeks
Djulis-Buckwheat
Ingest Djulis-Buckwheat drink 100ml/day for 8 weeks
Buckwheat
Ingest Buckwheat drink 100ml/day for 8 weeks

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Taipei Medical University Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Change of blood pressure Baseline, 1, 2, 4, 6, and 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Completed NCT02551640 - Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients N/A
Recruiting NCT01483430 - Effect of Ginseol Kg1 on Blood Pressure Lowering Phase 3
Terminated NCT01295216 - Use of Mobile Technology to Prevent Progression of Pre-hypertension in Latin American Urban Settings N/A
Completed NCT01637909 - Korean Life-Style Modification Effects on Blood Pressure N/A
Unknown status NCT01308983 - Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension Phase 4
Active, not recruiting NCT03596099 - Rice Vinegar as an Intervention to Lower Blood Pressure in Adults With Prehypertension and 10-year CVD Risk <10% N/A
Completed NCT04326686 - Measuring Individual Responses to a Wholegrains and Nuts Intervention to Reduce Blood Pressure in Prehypertension N/A
Completed NCT03898518 - The Effects of a Jump Rope Exercise Program on Body Composition and Self-efficacy in Obese Adolescent Girls N/A
Terminated NCT01983462 - Vascular Dysfunction in Human Obesity Hypertension Phase 2
Completed NCT01458496 - Health Coaching to Effect Lifestyle Behaviour Change N/A
Completed NCT01472692 - Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure Phase 4
Completed NCT03266510 - Inspiratory Muscle Strength Training to Improve Blood Pressure and Physiological Function N/A
Completed NCT02998840 - A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure Phase 2
Completed NCT01974570 - Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects Phase 2
Completed NCT02326766 - Blood Pressure Lowering Effect of Supplementation With Korea Red Ginseng Associated With Reductions in Circulating Lp-PLA2 Activity and Lysophospatidylcholines and an Increase in Dihydrobiopterin in Prehypertensive Subjects Phase 3
Completed NCT01395329 - Nebivolol and the Endothelin (ET)-1 System Phase 4
Completed NCT01331486 - Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract Phase 1
Completed NCT05274971 - Diet and Exercise on Ambulatory Blood Pressure N/A
Active, not recruiting NCT02371317 - Stress Management for High Blood Pressure N/A